Plesselova, Simona
Calar, Kristin
Axemaker, Hailey
Sahly, Emma
Bhagia, Amrita
Faragher, Jessica L.
Fink, Darci M.
de la Puente, Pilar http://orcid.org/0000-0001-5953-1197
Funding for this research was provided by:
National Cancer Institute (R21CA259158)
Sanford Health Foundation
National Institute of Health (R25HD097633, 5P20GM103548)
American Cancer Society (RSG-23-1149466-01-CDP)
Article History
Received: 18 February 2024
Accepted: 26 July 2024
First Online: 14 September 2024
Declarations
:
: Dr. Pilar de la Puente and Kristin Calar have a patent for the 3D culture method described in this manuscript, US Patent Application #2022/0228124. Pilar de la Puente is the co-founder of Cellatrix LLC; however, there has been no contribution of the aforementioned entity to the current study. Simona Plesselova, Hailey Axemaker, Emma Sahly, Amrita Bhagia, Jessica Faragher, and Darci Fink state no conflicts of interest.
: This research did not involve animal experiments. The studies involving human participants were reviewed and approved by Sanford Health Institutional Review Board. The patients/participants provided their written informed consent to participate in this study.